San Francisco, CA, United States of America

Scott Bidlingmaier

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):

Title: Scott Bidlingmaier: Innovator in Cancer Therapeutics

Introduction

Scott Bidlingmaier is a prominent inventor based in San Francisco, CA. He has made significant contributions to the field of cancer therapeutics, holding a total of 5 patents. His work focuses on innovative approaches to targeting cancer cells, particularly through the use of engineered antibodies.

Latest Patents

Among his latest patents are groundbreaking inventions such as "Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics." This patent describes human anti-CD46 antibodies that can internalize and enter tumor cells via the macropinocytosis pathway. Additionally, it includes antibody-drug conjugates (ADCs) designed for the diagnostic and therapeutic targeting of CD46-overexpressing tumors. Another notable patent is "Engineered antibodies and uses thereof," which relates to an engineered antibody that co-engages a cell type-selective antigen and a signaling receptor on a target cell. This innovation has the potential to modulate signaling pathways in target cells, offering new avenues for disease treatment.

Career Highlights

Scott Bidlingmaier is affiliated with the University of California, where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential impact on treatment methodologies and patient outcomes.

Collaborations

He collaborates with esteemed colleagues such as Bin Liu and Yang Su, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Scott Bidlingmaier's contributions to the field of cancer therapeutics through his patents and collaborations highlight his role as a leading inventor. His innovative approaches are paving the way for new treatment options in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…